24/7 Market News Snapshot 09 July, 2025 – Personalis, Inc. Common Stock (NASDAQ:PSNL)

July 9, 2025

DENVER, Colo., 09 July, 2025 (www.247marketnews.com) – (Nasdaq:PSNL) are discussed in this article.
Personalis, Inc. (Nasdaq:PSNL) has demonstrated notable bullish activity in the financial markets, opening at $6.92 and witnessing an 8.57% rise, currently trading at $7.448 with a substantial trading volume of 1.86 million shares. This upward trajectory is indicative of strong investor interest, and analysts suggest that maintaining momentum above $7.50 could lead to a breakout, with potential resistance levels around $8.00. Investors are advised to monitor the Relative Strength Index (RSI) for possible overbought conditions that may signal a pullback.

Simultaneously, Personalis has announced an important expansion of its strategic collaboration with Tempus AI, Inc. (Nasdaq:TEM), now including colorectal cancer (CRC) in their commercialization agreement. The partnership will leverage the NeXT Personal® ultra-sensitive, tumor-informed minimal residual disease (MRD) testing platform, which is also applicable for breast and lung cancers, as well as solid tumor immunotherapy monitoring.

This strategic move follows promising interim results from the VICTORI study that highlighted the test’s ability to effectively detect early cancer recurrence. With over 150,000 new colorectal cancer diagnoses each year, the collaboration is poised to significantly influence patient management and provide vital insights for oncologists and cancer survivors alike.

Under the amended agreement, Tempus will be the exclusive commercial partner for this new indication, extending the collaboration through November 2029, while enhancing exclusivity until 2028 for all four indications. Chris Hall, CEO of Personalis, emphasized that this expanded collaboration is central to their ‘Win in MRD’ initiative, aimed at granting patients greater peace of mind regarding the risk of cancer recurrence.

By uniting Personalis’s advanced MRD testing capabilities with Tempus’s broad oncologist network, which encompasses over half of U.S. oncologists, the partnership seeks to deliver crucial diagnostic tools essential for personalized patient management and reinforcing the company’s commitment to improving cancer care.

Related news for (PSNL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.